Business
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants --\n\n\n-- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours --\n\n\n-- No Severe or Serious Adverse Events with Single-Dose Administration of RLYB116 --\n\n\n-- Phase 1 Multiple Ascending Dose Study of RLYB116 Ongoing; Preliminary Safety, PK, and PD Data Expected in 4Q 2023 --\n\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented clinical data in a poster from the Phase 1 first-in-human single ascending dose (SAD) clinical study in healthy participants of RLYB116. RLYB116 is an innovative potentially long-acting, subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases. The poster presentation took place at the 29th International Complement Workshop (ICW), in Newcastle, UK.\n\n\nThe data demonstrated that single-dose administration of RLYB116 at the two higher doses of 100 mg and 300 mg resulted in maximum exposures of greater than 1 µM and 3 µM, respectively, and greater than 99% reductions in free C5 concentrations. Subcutaneously administered RLYB116 was observed to be generally well-tolerated as a single 100 mg or 300 mg dose, with mild to moderate adverse events and no drug-related serious adverse events.\n\n\n“The results presented today at ICW continue to support our belief in the potential use of RLYB116 for the treatment of a broad range of complement-mediated diseases. These single-dose data suggest that RLYB116 could be a highly innovative C5 inhibitor with the potential to address significant unmet medical need for patients,” commented Eric Watsky, M.D., Rallybio RLYB116 Program Lead. “We remain on track to report initial data from the Phase 1 multiple ascending dose study of RLYB116 and disclosing our indication strategy in the fourth quarter of 2023.”\n\n\nThe poster can be viewed on the Publications & Presentations page of the company’s website: https://rallybio.com/publications-presentations/\n\n\nAddition...